Combination of Asciminib plus Nilotinib or Asciminib plus Dasatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results

被引：4

作者：

DeAngelo, Daniel J. ^{[1
]}

Mauro, Michael J. ^{[2
]}

Kim, Dong-Wook ^{[3
]}

Cortes, Jorge ^{[4
]}

Rea, Delphine ^{[5
]}

Hughes, Timothy P. ^{[6
,7
]}

Minami, Hironobu ^{[8
]}

Breccia, Massimo ^{[9
]}

Talpaz, Moshe ^{[10
]}

Hochhaus, Andreas ^{[11
]}

Goh, Yeow Tee ^{[12
]}

Le Coutre, Philipp D. ^{[13
]}

Sondhi, Manu ^{[14
]}

Mishra, Kaushal ^{[14
]}

Hourcade-Potelleret, Florence ^{[15
]}

Vanasse, Gary ^{[15
]}

Aimone, Paola ^{[15
]}

Lang, Fabian ^{[16
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Catholic Univ Korea, Seoul St Marys Hosp, Leukemia Res Inst, Seoul, South Korea

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[5] Hop St Louis, Paris, France

[6] SA Pathol, Adelaide, SA, Australia

[7] Univ Adelaide, South Australian Hlth & Med Res Inst, Adelaide, SA, Australia

[8] Kobe Univ Hosp, Kobe, Hyogo, Japan

[9] Univ Roma La Sapienza, Rome, Italy

[10] Univ Michigan, Ann Arbor, MI 48109 USA

[11] Univ Klinikum Jena, Abt Hamatol Onkol, Jena, Germany

[12] Singapore Gen Hosp, Singapore, Singapore

[13] Charite Univ Med Berlin, Berlin, Germany

[14] Novartis Pharmaceut, E Hanover, NJ USA

[15] Novartis Pharma AG, Basel, Switzerland

[16] Goethe Univ Frankfurt Main, Frankfurt, Germany

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷

关键词：

asciminib; tyrosine kinase inhibitor; clinical trial; CML; chronic myelogenous leukemia;

D O I：

10.1016/j.clml.2019.07.236

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CML-102

引用

页码：S290 / S291

页数：3

共 50 条

[21] Real-World Effectiveness of Asciminib in Patients with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: A Global Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)
Milojkovic, Dragana
Blijlevens, Nicole
Kwong, Yok-Lam
Zaidi, Uzma
Castagnetti, Fausto
Gallipoli, Paolo
Miggiano, Maria Cristina
Westerweel, Peter E.
Chen, Melissa
Hernandez, Carmen Garcia
Kell, William J.
Vachhani, Pankit
Agarwal, Neha
Colasante, Alessandra
Meka, Sridhar
Smyth, Aoife
Ferreira, Germano
Janssen, Jeroen J. W. M.
BLOOD, 2023, 142
[22] Efficacy and Safety of Asciminib in Heavily Pretreated Patients with Philadelphia Chromosome-Positive (Ph plus ) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with Sensitivity to Tyrosine Kinase Inhibitors (TKIs)
Hughes, Timothy
Mauro, Michael
Kim, Dong-Wook
Cortes, Jorge
Rea, Delphine
Minami, Hironobu
Breccia, Massimo
DeAngelo, Daniel
Hochhaus, Andreas
Goh, Yeow-Tee
le Coutre, Philipp
Lang, Fabian
Cacciatore, Silvia
Aimone, Paola
Stenson, Laura
Polydoros, Fotis
Talpaz, Moshe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S235 - S235
[23] Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib
Hayashi, Yoshiki
Nakamae, Hirohisa
Katayama, Takako
Nakane, Takahiko
Koh, Hideo
Nakamae, Mika
Hirose, Asao
Hagihara, Kiyoyuki
Terada, Yoshiki
Nakao, Yoshitaka
Hino, Masayuki
LEUKEMIA & LYMPHOMA, 2012, 53 (06) : 1084 - 1089
[24] Bosutinib As Third-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 48-Month Update of a Phase 1/2 Study
Gambacorti-Passerini, Carlo
Khoury, H. Jean
Kantarjian, Hagop M.
Lipton, Jeffrey H.
Kim, Dong-Wook
Schafhausen, Philippe
Matczak, Ewa M.
Leip, Eric
Noonan, Kay
Bruemmendorf, Tim H.
Cortes, Jorge E.
BLOOD, 2014, 124 (21)
[25] Feasibility of first line nilotinib plus Peginterferon-α2b in chronic phase of chronic myeloid leukemia (CML): Results of the pilot phase of the German CML V (TIGER)-study
Schenk, T.
Eigendorff, E.
Bruemmendorf, T. H.
Burchert, A.
le Coutre, P.
Saussele, S.
Stegelmann, F.
Haenel, M.
Staib, P.
Lindemann, H. -W
Lange, E.
Mueller, L.
Schwarzer, A.
Jentsch-Ullrich, K.
Schenk, M.
Greiner, J.
Fabisch, C.
Pfirrmann, M.
Hochhaus, A.
ONCOLOGY RESEARCH AND TREATMENT, 2015, 38 : 183 - 183
[26] Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study
Gugliotta, Gabriele
Annunziata, Mario
Capodanno, Isabella
Rapezzi, Davide
Attolico, Immacolata
Vincelli, Iolanda Donatella
Tiribelli, Mario
Malato, Alessandra
Pizzuti, Michele
Accurso, Vincenzo
Bonifacio, Massimiliano
Galimberti, Sara
Loglisci, Giuseppina
Abruzzese, Elisabetta
Bocchia, Monica
Gozzini, Antonella
Bergamaschi, Micaela
Miggiano, Maria Cristina
Tafuri, Agostino
Sanpaolo, Grazia
Binotto, Gianni
Castagnetti, Fausto
Specchia, Giorgina
Di Raimondo, Francesco
Cavo, Michele
Rosti, Gianantonio
Foa, Robin
Saglio, Giuseppe
Breccia, Massimo
Stagno, Fabio
BLOOD, 2020, 136
[27] Hypercvad Plus Imatinib or Dasatinib for Patients with Lymphoid Blastic Phase of Chronic Myeloid Leukemia
Strati, Paolo
Kantarjian, Hagop M.
Thomas, Deborah A.
O'Brien, Susan M.
Jabbour, Elias J.
Quintas-Cardama, Alfonso
Borthakur, Gautam
Faderl, Stefan
Ravandi, Farhad
Cortes, Jorge E.
BLOOD, 2012, 120 (21)
[28] Asciminib Provides Durable Responses and a Favorable Safety Profile in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with the T315I Mutation in a Phase 1 Study
Cortes, Jorge E.
Hughes, Timothy P.
Mauro, Michael J.
Hochhaus, Andreas
Rea, Delphine
Goh, Yeow-Tee
Janssen, J. J. W. M.
Heinrich, Michael C.
Talpaz, Moshe
Etienne, Gabriel
Breccia, Massimo
Deininger, Michael
Le Coutre, Philipp
Lang, Fabian
Polydoros, Fotis
Cacciatore, Silvia
Stenson, Laura
Kim, Dong-Wook
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S335 - S336
[29] Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib.
Cortes, Jorge E.
Khoury, H. Jean
Lipton, Jeff H.
Gambacorti-Passerini, Carlo
Bruemmendorf, Tim H.
Kim, Dong-Wook
Leip, Eric
Kelly, Virginia
Besson, Nadine
Turnbull, Kathleen
Kantarjian, Hagop M.
BLOOD, 2012, 120 (21)
[30] Cardiovascular Hospitalization in Patients Treated with Dasatinib or Nilotinib in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients in Routine Clinical Practice
Mauro, Michael J.
Chen, Clara
Cortes, Jorge E.
Gambacorti-Passerini, Carlo
Sen, Ginny P.
Gajavelli, Srikanth
Davis, Catherine
Michallet, Mauricette
BLOOD, 2018, 132

← 1 2 3 4 5 →